Inj. inebilizumab-cdon, 1 mg
Products billed under this code include Uplizna.
Payment limit per 1 MG, by effective quarter, 4Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Uplizna.
Payment limit per 1 MG, by effective quarter, 4Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Uplizna | Amgen Inc | 75987-0150-03 | 300 | $153,471.90 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $511.573 | +$0.921 | 1 MG | Inj. inebilizumab-cdon, 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $510.652 | +$15.107 | 1 MG | Inj. inebilizumab-cdon, 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $495.545 | $0.00 | 1 MG | Inj. inebilizumab-cdon, 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $495.545 | $0.00 | 1 MG | Inj. inebilizumab-cdon, 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $495.545 | +$1.111 | 1 MG | Inj. inebilizumab-cdon, 1 mg | v1, posted September 8, 2026 |
| 3Q25 | $494.434 | +$10.031 | 1 MG | Inj. inebilizumab-cdon, 1 mg | v1, posted March 10, 2026 |
| 2Q25 | $484.403 | $0.00 | 1 MG | Inj. inebilizumab-cdon, 1 mg | v1, posted March 10, 2026 |
| 1Q25 | $484.403 | $0.00 | 1 MG | Inj. inebilizumab-cdon, 1 mg | v1, posted December 19, 2025 |
| 4Q24 | $484.403 | +$0.565 | 1 MG | Inj. inebilizumab-cdon, 1 mg | v1, posted June 11, 2025 |
| 3Q24 | $483.838 | +$10.325 | 1 MG | Inj. inebilizumab-cdon, 1 mg | v1, posted June 11, 2025 |
| 2Q24 | $473.513 | $0.00 | 1 MG | Inj. inebilizumab-cdon, 1 mg | v1, posted March 11, 2025 |
| 1Q24 | $473.513 | $0.00 | 1 MG | Inj. inebilizumab-cdon, 1 mg | v1, posted December 19, 2024 |
| 4Q23 | $473.513 | +$1.21 | 1 MG | Inj. inebilizumab-cdon, 1 mg | v1, posted October 10, 2024 |
| 3Q23 | $472.303 | +$9.436 | 1 MG | Inj. inebilizumab-cdon, 1 mg | v1, posted June 5, 2024 |
| 2Q23 | $462.867 | $0.00 | 1 MG | Inj. inebilizumab-cdon, 1 mg | v1, posted February 23, 2024 |
| 1Q23 | $462.867 | $0.00 | 1 MG | Inj. inebilizumab-cdon, 1 mg | v1, posted December 6, 2023 |
| 4Q22 | $462.867 | $0.00 | 1 MG | Inj. inebilizumab-cdon, 1 mg | v1, posted June 22, 2023 |
| 3Q22 | $462.867 | $0.00 | 1 MG | Inj. inebilizumab-cdon, 1 mg | v1, posted June 9, 2023 |
| 2Q22 | $462.867 | +$0.249 | 1 MG | Inj. inebilizumab-cdon, 1 mg | v1, posted December 14, 2022 |
| 1Q22 | $462.618 | +$4.411 | 1 MG | Inj. inebilizumab-cdon, 1 mg | v1, posted June 8, 2022 |
| 4Q21 | $458.207 | – | 1 MG | Inj. inebilizumab-cdon, 1 mg | v1, posted June 2, 2022 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.